CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,008 enrolled
Drug / intervention
Cisatracurium Besylatedrug
Likely dose
Cisatracurium Besylate 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02509078
NCT02509078Phase 3Completed
CompareCT.gov

Reevaluation Of Systemic Early Neuromuscular Blockade

Massachusetts General Hospital·interventional·Posted Jul 27, 2015·Updated Aug 13, 2019

In Brief

A Phase 3 clinical trial evaluating Cisatracurium Besylate for Acute Respiratory Distress Syndrome. Completed, enrolled 1,008 participants across 44 sites.

Detailed Summary

This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be discouraged.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Respiratory Distress Syndrome
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 27, 2015
Enrollment StartJan 4, 2016
Primary CompletionJul 3, 2018
Study CompletionApr 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.9 years ago

Interventions

Cisatracurium Besylatedrug

Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.